489 related articles for article (PubMed ID: 26335914)
1. Interferon-Free Therapy for Hepatitis C in Liver Transplant Recipients.
Ueda Y; Uemoto S
Transplantation; 2016 Jan; 100(1):54-60. PubMed ID: 26335914
[TBL] [Abstract][Full Text] [Related]
2. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.
Charlton M; Gane E; Manns MP; Brown RS; Curry MP; Kwo PY; Fontana RJ; Gilroy R; Teperman L; Muir AJ; McHutchison JG; Symonds WT; Brainard D; Kirby B; Dvory-Sobol H; Denning J; Arterburn S; Samuel D; Forns X; Terrault NA
Gastroenterology; 2015 Jan; 148(1):108-17. PubMed ID: 25304641
[TBL] [Abstract][Full Text] [Related]
3. Current management and perspectives for HCV recurrence after liver transplantation.
Coilly A; Roche B; Samuel D
Liver Int; 2013 Feb; 33 Suppl 1():56-62. PubMed ID: 23286847
[TBL] [Abstract][Full Text] [Related]
4. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.
Curry MP; Forns X; Chung RT; Terrault NA; Brown R; Fenkel JM; Gordon F; O'Leary J; Kuo A; Schiano T; Everson G; Schiff E; Befeler A; Gane E; Saab S; McHutchison JG; Subramanian GM; Symonds WT; Denning J; McNair L; Arterburn S; Svarovskaia E; Moonka D; Afdhal N
Gastroenterology; 2015 Jan; 148(1):100-107.e1. PubMed ID: 25261839
[TBL] [Abstract][Full Text] [Related]
5. Concise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infection.
Weiler N; Zeuzem S; Welker MW
World J Gastroenterol; 2016 Nov; 22(41):9044-9056. PubMed ID: 27895394
[TBL] [Abstract][Full Text] [Related]
6. Clinical decompensation after achieving SVR with sofosbuvir, daclatasvir and ribavirin in a patient with recurrent HCV post-liver transplant.
Kalafateli M; Dusheiko G; Manousou P
J Gastrointestin Liver Dis; 2015 Jun; 24(2):257-8. PubMed ID: 26114189
[No Abstract] [Full Text] [Related]
7. Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus.
Patel N; Bichoupan K; Ku L; Yalamanchili R; Harty A; Gardenier D; Ng M; Motamed D; Khaitova V; Bach N; Chang C; Grewal P; Bansal M; Agarwal R; Liu L; Im G; Leong J; Kim-Schluger L; Odin J; Ahmad J; Friedman S; Dieterich D; Schiano T; Perumalswami P; Branch A
World J Gastroenterol; 2016 Mar; 22(9):2844-54. PubMed ID: 26973423
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic monitoring of immunosuppressive effects indicates reduced cyclosporine activity during telaprevir therapy.
Roos K; Gotthardt D; Giese T; Schnitzler P; Stremmel W; Czock D; Eisenbach C
Liver Transpl; 2014 Sep; 20(9):1106-17. PubMed ID: 24890314
[TBL] [Abstract][Full Text] [Related]
9. Optimal therapy in hepatitis C virus liver transplant patients with direct acting antivirals.
Coilly A; Roche B; Duclos-Vallée JC; Samuel D
Liver Int; 2015 Jan; 35 Suppl 1():44-50. PubMed ID: 25377540
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C virus reinfection after liver transplantation: is there a role for direct antiviral agents?
Dall'Agata M; Gramenzi A; Biselli M; Bernardi M
World J Gastroenterol; 2014 Jul; 20(28):9253-60. PubMed ID: 25071318
[TBL] [Abstract][Full Text] [Related]
11. Management of hepatitis C infection before and after liver transplantation.
Fagiuoli S; Ravasio R; Lucà MG; Baldan A; Pecere S; Vitale A; Pasulo L
World J Gastroenterol; 2015 Apr; 21(15):4447-56. PubMed ID: 25914454
[TBL] [Abstract][Full Text] [Related]
12. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
[TBL] [Abstract][Full Text] [Related]
13. Functional Behavior of NKp46-Positive Intrahepatic Natural Killer Cells Against Hepatitis C Virus Reinfection After Liver Transplantation.
Tanimine N; Tanaka Y; Abe T; Piao J; Chayama K; Ohdan H
Transplantation; 2016 Feb; 100(2):355-64. PubMed ID: 26714120
[TBL] [Abstract][Full Text] [Related]
14. Management of recurrent hepatitis C virus after liver transplantation.
Jiménez-Pérez M; González-Grande R; Rando-Muñoz FJ
World J Gastroenterol; 2014 Nov; 20(44):16409-17. PubMed ID: 25469009
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C: New challenges in liver transplantation.
Filipec Kanizaj T; Kunac N
World J Gastroenterol; 2015 May; 21(19):5768-77. PubMed ID: 26019441
[TBL] [Abstract][Full Text] [Related]
16. Recurrent hepatitis C after liver transplant.
deLemos AS; Schmeltzer PA; Russo MW
World J Gastroenterol; 2014 Aug; 20(31):10668-81. PubMed ID: 25152571
[TBL] [Abstract][Full Text] [Related]
17. Treatment of hepatitis C in liver transplant patients: interferon out, direct antiviral combos in.
Price JC; Terrault NA
Liver Transpl; 2015 Apr; 21(4):423-34. PubMed ID: 25604355
[TBL] [Abstract][Full Text] [Related]
18. Management of HCV transplant patients with triple therapy.
Coilly A; Roche B; Duclos-Vallée JC; Samuel D
Liver Int; 2014 Feb; 34 Suppl 1():46-52. PubMed ID: 24373078
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology and outcome of hepatitis C relapse in transplant recipients.
Angelico M
Transplant Proc; 2011; 43(6):2457-8. PubMed ID: 21839293
[TBL] [Abstract][Full Text] [Related]
20. Timing of Hepatitis C Antiviral Therapy in Liver Transplant Recipients With Direct-acting Agents.
Suraweera D; Saab EG; Tong MJ; Saab S
Exp Clin Transplant; 2016 Jun; 14(3):243-51. PubMed ID: 27221717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
